CCR

Cat. No.

A15924

CAS No.

140926-75-6

NSC5844

Synonyms: RE640

NSC5844 is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.

Cat. No.

A16363

CAS No.

1780259-94-0

ZK-756326 dihydrochloride

ZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 μM.

Cat. No.

A16791

CAS No.

874911-96-3

ZK 756326

ZK 756326 is a nonpeptide agonist specifically targeting the CC chemokine receptor CCR8. It exhibits potent activity in modulating chemokine signaling pathways, making it a valuable tool in studies related to immune response and inflammation. This compound is useful for researchers investigating the role of CCR8 in various biological processes and potential therapeutic applications.

Cat. No.

A18643

CAS No.

950195-51-4

LMD-009

LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM.

Cat. No.

A20056

CAS No.

1427058-33-0

E6130

E6130 is an orally available and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.

Cat. No.

A59522

CAS No.

1229603-37-5

AZD2423

AZD2423 functions as a negative allosteric modulator of the CCR2 chemokine receptor, exhibiting potent selectivity and oral bioavailability. With an IC50 value of 1.2 nM for CCR2-mediated Ca2+ flux, this compound is valuable for investigating the role of CCR2 in various physiological and pathological processes. AZD2423 is useful in research applications related to inflammation, cancer, and immune system modulation.

Cat. No.

A59553

CAS No.

521979-59-9

LMD-902

LMD-902 is a potent CCR8 agonist with an EC50 of 15 nM, demonstrating enhanced binding capacity influenced by critical residues such as PheVI:16. This compound is instrumental in researching inflammatory diseases, including bronchial asthma, as well as central nervous system disorders such as multiple sclerosis. Its specificity and efficacy make LMD-902 a valuable tool for advancing understanding in these therapeutic areas.

Cat. No.

A59570

CAS No.

954371-52-9

CH0076989

CH0076989 is a selective agonist of the CCR3 receptor that activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimeric receptor lacking the CCR3 amino-terminus. This compound exhibits a direct interaction with the transmembrane helices of CCR3; activity is abolished by mutations of key residues Y41, Y113, and E287. CH0076989 is ideal for research into inflammation and allergic diseases, including asthma, making it a valuable tool for understanding these pathological conditions.

Cat. No.

A59583

CAS No.

521979-66-8

LMD-584

LMD-584 is a selective agonist of CCR8, a chemokine receptor involved in immune responses and inflammation. This compound demonstrates significant biological activity in modulating CCR8 signaling pathways, making it a valuable tool for research applications focused on immune cell trafficking and related pathologies. LMD-584 may aid in understanding the role of CCR8 in various diseases, including cancer and autoimmune disorders.

Cat. No.

A59584

CAS No.

960296-78-0

CCR5 modulator-1

CCR5 modulator-1 is a selective modulator of the CCR5 chemokine receptor. This compound plays a significant role in the regulation of inflammatory processes and can be applied in research aimed at understanding various inflammatory diseases. Its use may provide insights into therapeutic strategies targeting CCR5-related pathways.

Cat. No.

A59594

CAS No.

1111300-51-6

CCR9 modulator-1

CCR9 modulator-1 is a selective modulator of the chemokine receptor CCR9, primarily involved in T-cell trafficking and immune response regulation. This compound demonstrates significant potential in influencing CCR9-mediated immune pathways, making it a valuable tool for the study of inflammatory diseases such as Crohn's disease and other gastrointestinal disorders. Researchers can utilize CCR9 modulator-1 to explore therapeutic strategies targeting CCR9 in various immunological contexts.